Cosmos Health Inc.
Cosmos Health Inc. is a U.S.-listed healthcare distribution and branded-products company with operations centered in Greece, the UK and other European markets. It wholesales pharmaceuticals and healthcare products, manufactures and markets branded generics and OTC products, and also sells its proprietary Sky Premium Life nutraceutical line through retail and e-commerce channels.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDistribution of prescription drugs, OTC products, medical devices and related healthcare goods to pharmacies and other healthcare buyers.
Production, promotion and sale of licensed branded generics and OTC products in Europe.
Proprietary Sky Premium Life supplements sold through retail, e-commerce and distribution partners.
GMP-based manufacturing services and production capacity used for third-party and in-house products.
Direct-to-consumer telemedicine platform and related healthcare services through ZipDoctor.
Customers
Cosmos sells primarily to pharmacies, hospitals, private clinics and other pharmaceutical wholesalers that need reliable supply of medicines and healthcare products. It also serves end consumers through Sky Premium Life on Amazon UK and through distribution partners such as Pharmalink in the UAE. The customer mix reflects a hybrid model: B2B wholesale and manufacturing on one side, and branded consumer health products on the other.
Buy pharmaceuticals, OTC products and supplements for daily resale and patient demand.
Purchase medicines, medical devices and healthcare consumables for clinical use.
Source broad product assortments for onward distribution in local markets.
Purchase Sky Premium Life products through Amazon UK and partner channels for wellness use.
Use ZipDoctor for affordable 24/7 access to physicians and mental health counselors.
Strategy
Cosmos is pursuing a mix of organic growth and acquisitions to expand its distribution network, product portfolio and manufacturing capacity. Management is emphasizing vertical integration, R&D for proprietary pharmaceuticals and nutraceuticals, and broader international reach through retailers, pharmacies, e-commerce and contract manufacturing partnerships.
Adds customer bases, distribution routes and scale quickly in fragmented markets.
Higher-margin proprietary products can improve mix versus pure wholesale.
Own manufacturing and GMP capabilities can support margin expansion and control.
Broader market access reduces reliance on any single country or channel.
Geography
The company’s operating footprint is centered in Greece and the UK, with distribution and manufacturing assets supporting broader European sales. It also has commercial expansion into the UAE through an exclusive Sky Premium Life distribution agreement, and management has described opportunities to distribute test kits across Europe on a non-exclusive basis. Geography matters because the business depends on local regulatory approvals, GDP-compliant logistics and country-specific healthcare spending patterns.
Risks
The company has disclosed substantial doubt about its ability to continue as a going concern, making financing access a central risk. Its business is also exposed to execution risk from acquisitions, regulatory and supply-chain complexity across multiple countries, and margin pressure in wholesale healthcare markets where pricing and reimbursement can be volatile.
Management says substantial doubt exists and expects to rely on cash, debt/equity financing or loans.
Exposure: Corporate funding and operating continuity
Growth depends on integrating acquired networks, systems and customer bases without disrupting service.
Exposure: Bikas and other acquired distribution assets
Pharmaceutical wholesale, GMP manufacturing and cross-border sales require ongoing compliance.
Wholesale and manufacturing depend on timely sourcing of quality raw materials and finished goods.
The company operates in multiple currencies and tax jurisdictions, affecting earnings and cash flow.
Accounting
Judgemental itemsDifferent sales channels may recognize revenue at different points in the transaction cycle.
Impact: Affects quarterly revenue timing and gross margin comparability
Foreign subsidiaries are translated using period-end and average exchange rates.
Impact: Can create volatility in equity and reported earnings
The company has U.S. net operating losses and foreign tax liabilities that require judgment.
Impact: Affects tax expense and realizability of tax assets
Acquisitions such as Bikas created intangible assets that must be supported by future cash flows.
Impact: Potential impairment charges if synergies do not materialize
Similar listed companies
Publicly listed companies with a comparable business focus.
Skye Bioscience, Inc.
SKYE · Pharmaceutical Preparations
Impact BioMedical, Inc
IBO · Pharmaceutical Preparations
Hims & Hers Health, Inc.
HIMS · Services-Offices & Clinics of Doctors of Medicine
Nature's Sunshine Products, Inc
NATR · Pharmaceutical Preparations
Nature’s Sunshine Products is a U.S.-based natural health and wellness company that manufactures and sells nutritional supplements and personal care products.
Alps Group Inc
ALPWF · Services-Health Services
Alps Group Inc is a United States-listed healthcare services and biotechnology platform with operating roots in Malaysia and Southeast Asia.
Kairos Pharma, LTD.
KAPA · Pharmaceutical Preparations
Last updated: 24/09/2026